The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder

References

• Greenberg PE, Sisitsky T, Kessler RC. et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999;60:427–351. Greenberg PE, Sisitsky T, Kessler RC. et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999;60:427–35
   PubMed Web of Science ®Google Scholar
• Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002;16:162–712. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002;16:162–71
   PubMed Web of Science ®Google Scholar
• Maier W, Gansicke M, Freyberger HJ. et al. Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: a valid diagnostic entity?. Acta Psychiatr Scand 2000;101:29–363. Maier W, Gansicke M, Freyberger HJ. et al. Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: a valid diagnostic entity?. Acta Psychiatr Scand 2000;101:29–36
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed.. Washington1994 Author4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington1994 Author
   Google Scholar
• Rapaport MH, Clary C, Fayyad R. et al. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry 2005;162:1171–85. Rapaport MH, Clary C, Fayyad R. et al. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry 2005;162:1171–8
   PubMed Web of Science ®Google Scholar
• Pollack MH, Endicott J, Liebowitz M. et al. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res 2008 [in press] [e-published ahead of print; DOI 10.1016/j.jpsychires.2007.11.006]6. Pollack MH, Endicott J, Liebowitz M. et al. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res 2008[in press] [e-published ahead of print; DOI 10.1016/j.jpsychires.2007.11.006]
   Web of Science ®Google Scholar
• Bech P. Social functioning: should it become an endpoint in trials of antidepressants?. CNS Drugs 2005;19:313–247. Bech P. Social functioning: should it become an endpoint in trials of antidepressants?. CNS Drugs 2005;19:313–24
   PubMed Web of Science ®Google Scholar
• Rush AJ, Kraemer HC, Sackeim HA. et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006;31:1841–538. Rush AJ, Kraemer HC, Sackeim HA. et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006;31:1841–53
   PubMed Web of Science ®Google Scholar
• Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. J Am Med Assoc 2003;289:3152–609. Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. J Am Med Assoc 2003;289:3152–60
   PubMed Web of Science ®Google Scholar
• Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999;60 Suppl 22:29–3410. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999;60 Suppl 22:29–34
   PubMedGoogle Scholar
• Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry 2001;62 Suppl 12:5–911. Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry 2001;62 Suppl 12:5–9
   PubMed Web of Science ®Google Scholar
• Fava M, Mallinckrodt CH, Detke MJ. et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?. J Clin Psychiatry 2004;65:521–3012. Fava M, Mallinckrodt CH, Detke MJ. et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?. J Clin Psychiatry 2004;65:521–30
   PubMed Web of Science ®Google Scholar
• Kroenke K, Price RK. Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. Arch Intern Med 1993;153:2474–8013. Kroenke K, Price RK. Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. Arch Intern Med 1993;153:2474–80
   PubMed Web of Science ®Google Scholar
• Carter CS, Maddock RJ. Chest pain in generalized anxiety disorder. Int J Psychiatry Med 1992;22:291–814. Carter CS, Maddock RJ. Chest pain in generalized anxiety disorder. Int J Psychiatry Med 1992;22:291–8
   PubMed Web of Science ®Google Scholar
• Katon WJ, Walker EA. Medically unexplained symptoms in primary care. J Clin Psychiatry 1998;59 Suppl 20:15–2115. Katon WJ, Walker EA. Medically unexplained symptoms in primary care. J Clin Psychiatry 1998;59 Suppl 20:15–21
   PubMed Web of Science ®Google Scholar
• Gureje O, Simon GE, Ustun TB. et al. Somatization in cross-cultural perspective: a World Health Organization study in primary care. Am J Psychiatry 1997;154:989–9516. Gureje O, Simon GE, Ustun TB. et al. Somatization in cross-cultural perspective: a World Health Organization study in primary care. Am J Psychiatry 1997;154:989–95
   PubMed Web of Science ®Google Scholar
• Kirmayer LJ, Robbins JM, Dworkind M. et al. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993;150:734–4117. Kirmayer LJ, Robbins JM, Dworkind M. et al. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993;150:734–41
   PubMed Web of Science ®Google Scholar
• Allgulander C, Koponen H, Erickson J. et al. Duloxetine as an effective treatment for improving painful physical symptoms and functioning associated with generalized anxiety disorder. Depress Anxiety 2007;24:275–818. Allgulander C, Koponen H, Erickson J. et al. Duloxetine as an effective treatment for improving painful physical symptoms and functioning associated with generalized anxiety disorder. Depress Anxiety 2007;24:275–8
   Web of Science ®Google Scholar
• Russell JM, Weisberg R, Fava M. et al. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety 2007 [in press] [e-published ahead of print; DOI 10.1002/da.20337]19. Russell JM, Weisberg R, Fava M. et al. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety 2007[in press] [e-published ahead of print; DOI 10.1002/da.20337]
   Google Scholar
• Hartford J, Kornstein S, Liebowitz M. et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007;22:167–7420. Hartford J, Kornstein S, Liebowitz M. et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007;22:167–74
   PubMed Web of Science ®Google Scholar
• Nicolini H, Bakish D, Duenas H. et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release, and placebo-controlled trial. Psychol Med [in press]21. Nicolini H, Bakish D, Duenas H. et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release, and placebo-controlled trial. Psychol Med[in press]
   PubMed Web of Science ®Google Scholar
• Koponen H, Allgulander C, Erickson J. et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 2007;9:100–722. Koponen H, Allgulander C, Erickson J. et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 2007;9:100–7
   PubMedGoogle Scholar
• Rynn M, Russell J, Erickson J. et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2007;25:182–923. Rynn M, Russell J, Erickson J. et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2007;25:182–9
   Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50–524. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50–5
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11 Suppl 3:89–9525. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11 Suppl 3:89–95
   PubMed Web of Science ®Google Scholar
• DeLoach LJ, Higgins MS, Caplan AB. et al. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998;86:102–626. DeLoach LJ, Higgins MS, Caplan AB. et al. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998;86:102–6
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH. et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59 Suppl 20:22–5727. Sheehan DV, Lecrubier Y, Sheehan KH. et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59 Suppl 20:22–57
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–7028. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–70
   PubMed Web of Science ®Google Scholar
• Guy WThe clinician global severity and impression scalesECDEU assessment manual for psychopharmacology [76–338]. Rockville(MD): US Dept Health, Education, and Welfare1976. 218–2229. Guy WThe clinician global severity and impression scalesECDEU assessment manual for psychopharmacology [76–338]. Rockville(MD): US Dept Health, Education, and Welfare1976. 218–22
   Google Scholar
• Lipman RS, Covi L, Downing RW. et al. Pharmacotherapy of anxiety and depression: rationale and study design. Psychopharmacol Bull 1981;17:91–430. Lipman RS, Covi L, Downing RW. et al. Pharmacotherapy of anxiety and depression: rationale and study design. Psychopharmacol Bull 1981;17:91–4
   Google Scholar
• Raskin A, Schulterbrandt J, Reatig N. et al. Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J Nerv Ment Dis 1969;148:87–9831. Raskin A, Schulterbrandt J, Reatig N. et al. Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J Nerv Ment Dis 1969;148:87–98
   PubMed Web of Science ®Google Scholar
• Hamilton MDiagnosis and rating of anxietyStudies of anxietyLader MH: Brit J Psychiatr Spec Publication1969;3:76–932. Hamilton MDiagnosis and rating of anxietyStudies of anxietyLader MH: Brit J Psychiatr Spec Publication1969;3:76–9
   Google Scholar
• Leon AC, Olfson M, Portera L. et al. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 1997;27:93–10533. Leon AC, Olfson M, Portera L. et al. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 1997;27:93–105
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences, 2nd. Hillsdale (NJ): Lawrence Erlbaum Associates198834. Cohen J. Statistical power analysis for the behavioral sciences, 2nd. Hillsdale (NJ): Lawrence Erlbaum Associates1988
   Google Scholar
• Retherford RD, Choe MK. Statistical methods for causal analysis. New York (NY): John Wiley & Sons, Inc.199335. Retherford RD, Choe MK. Statistical methods for causal analysis. New York (NY): John Wiley & Sons, Inc.1993
   Google Scholar
• Johnson RA, Wichern DW. Applied multivariate statistical analysis. London (UK): Prentice Hall199236. Johnson RA, Wichern DW. Applied multivariate statistical analysis. London (UK): Prentice Hall1992
   Google Scholar
• Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry 2000;157:669–8237. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry 2000;157:669–82
   PubMed Web of Science ®Google Scholar
• Rickels K, Zaninelli R, McCafferty J. et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003;160:749–5638. Rickels K, Zaninelli R, McCafferty J. et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003;160:749–56
   PubMed Web of Science ®Google Scholar
• Wise TN, Meyers AL, Desaiah D. et al. The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder. J Clin Psychiatry 2007 [in press]39. Wise TN, Meyers AL, Desaiah D. et al. The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder. J Clin Psychiatry 2007[in press]
   Google Scholar
• Ressler KJ, Nemeroff CB. Role of norepinephrine in the pathophysiology of neuropsychiatric disorders. CNS Spectr 2001;6:663–7040. Ressler KJ, Nemeroff CB. Role of norepinephrine in the pathophysiology of neuropsychiatric disorders. CNS Spectr 2001;6:663–70
   PubMedGoogle Scholar
• Reneman L, Lavalaye J, Schmand B. et al. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’): preliminary findings. Arch Gen Psychiatry 2001;58:901–641. Reneman L, Lavalaye J, Schmand B. et al. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’): preliminary findings. Arch Gen Psychiatry 2001;58:901–6
   PubMed Web of Science ®Google Scholar
• Raskin J, Wiltse CG, Siegal A. et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900–942. Raskin J, Wiltse CG, Siegal A. et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900–9
   PubMed Web of Science ®Google Scholar